Addiction

Make treatment accessible for opioid use disorder during the COVID-19 pandemic

During the current pandemic Americans are dealing with a complete or near complete disruption of everyday life. It is the same for persons with opioid use disorder (OUD), but they are far from the...

Dangers of digital media addiction

The World Health Organization as well as several tech companies are encouraging on-line gaming with discounts and slogans such as, "Play your part, play at home." With schools closed, children suddenly have more time...

Opioid-induced respiratory depression

Be prepared and know the risks. Takeaways: Risk factors for opioid-induced respiratory depression include impaired rental clearance, high opioid tolerance, and sleep apnea history. Tools for assessing patient sedation levels include Richmond Agitation-Sedation Scale and...
cannabis

New research on possible adverse events to cannabis

A new study recently published in the Journal of Cannabis Research examines the potential “acute adverse reactions” associated with cannabis use. The study examined self-reported adverse reactions from 999 cannabis users and revealed that the...
cannabis

Cannabinoid hyperemesis syndrome explained

Learn how to identify this frequently misdiagnosed condition. Takeaways: Cannabinoid hyperemesis syndrome is a growing but poorly understood healthcare concern within the rising number of chronic, habitual cannabis users in the United States. Cannabinoid hyperemesis...

Who will care for society’s forgotten?

Editor's note: Theresa is a frequent contributor to the New York Times (NYT), and recently authored an Op-Ed on an issue that affects the public at large and the broader health care community. She covers...

Alcohol-related mortality rates on the rise

A new study published in Alcoholism Clinical & Experimental Research reveals that the amount of alcohol-related deaths in the United States has increased between 1999 and 2017. The study examined death certificates of people 16+...

FDA issues warning letter for medication-assisted treatment for opioid use disorder

The U.S. Food and Drug Administration (FDA) recently issued a warning letter to Alkermes, Inc. due to misbranding on the drug Vivitrol, which is used to prevent opioid dependence relapse. The letter was issued...

Legalized recreational marijuana may increase risk for cannabis use disorder

A recent study from JAMA Psychiatry examines this question: Has legalization of recreational marijuana in the United States affected the rates of cannabis use disorder (CUD)? The research was conducted through a repeated, cross-sectional, self-reported...

American Heart Association: E-cigarettes are not safe alternative

The American Heart Association (AHA) recently held its 2019 Scientific Sessions in Philadelphia PA. The sessions covered many topics, but one of the most impactful was a session on e-cigarettes and their adverse health...

Johns Hopkins Center for Psychedelic Research

In early September 2019, Johns Hopkins opened its new Center for Psychedelic and Consciousness Research, which explores the use of psychedelics on brain function, memory, and the brain’s biology. The center explores the use of...

New FDA guidelines on risks of smokeless tobacco products

For the first time ever, the U.S. Food and Drug Administration (FDA) has authorized eight Swedish Match USA, Inc. snus smokeless tobacco products to be marketed through the modified risk tobacco product (MRTP) pathway. Recently,...

How the opioid epidemic affects women

Opioid use disorder (OUD) has become such a prominent topic in today’s society that it’s hard to go one day without hearing news about new death statistics or pending litigation issues, but one aspect...